Limitations of point-of-care testing in the ED or ICU: A role for regional centralized toxicology laboratories

Clinical Pharmacology and Therapeutics

Volumn 88, Issue 3, 2010, Pages 295-298

  Wu, A H B ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ALCOHOL; CENTRAL STIMULANT AGENT; COCAINE; DIAMORPHINE; PHENCYCLIDINE; TETRAHYDROCANNABINOL;

DIAGNOSTIC ACCURACY; DRUG ABUSE; DRUG OVERDOSE; DRUG SCREENING; EMERGENCY WARD; HEALTH PROGRAM; HUMAN; INTENSIVE CARE UNIT; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NONHUMAN; NOTE; PATIENT COMPLIANCE; PERFORMANCE MEASUREMENT SYSTEM; POINT OF CARE TESTING; PRIORITY JOURNAL;

CHROMATOGRAPHY, LIQUID; DRUG MONITORING; EMERGENCY SERVICE, HOSPITAL; HUMANS; IMMUNOASSAY; INTENSIVE CARE UNITS; LABORATORY TECHNIQUES AND PROCEDURES; MASS SPECTROMETRY; POINT-OF-CARE SYSTEMS; SUBSTANCE ABUSE DETECTION; TIME FACTORS; TOXICOLOGY;

EID: 77955900384     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.45     Document Type: Note

References (12)

1. Moeller, K.E., Lee, K.C. & Kissack, J.C. Urine drug screening: practical guide for clinicians. Mayo Clin. Proc. 83, 66-76 (2008).
2. US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration. Drug Abuse Warning Network, 2006: National Estimates of Drug-Related Emergency Department Visits (August 2008).
3. Lewandrowski, K. et al. Implementation of point-of-care rapid urine testing for drugs of abuse In the emergency department of an academic medical center: impact on test utilization and ED length of stay. Am. J. Clin. Pathol. 129, 796-801 (2008).
4. Smith, F.P., Lora-Tamayo, C., Carvajal, R., Caddy, B. & Tagliaro, F. Assessment of an automated immunoassay based on kinetic interaction of microparticles in solution for determination of opiates and cocaine metabolite in urine. Ann. Clin. Biochem. 34, 81-84 (1997).
5. De la Torre, R., Domingo-Salvany, A., Badia, R., Gonzalez, G., McFarlane, D., San, L. et al. Clinical evaluation of the Triage analytic device for drugs-of-abuse testing. Clin. Chem. 42, 1433-1438 (1996).
6. Moody, D.E., Fang, W.B., Andrenyak, D.M., Monti, K.M. & Jones, C. A comparative evaluation of the instant-view 5-panel test card with OnTrak TesTcup Pro 5: comparison with gas chromatography-mass spectrometry. J. Anal. Toxicol. 30, 50-56 (2006).
7. Way, B.A., Walton, K.G., Koenig, J.W., Eveland, B.J. & Scott, M.G. Comparison between the CEDIA and EMIT II immunoassays for the determination of benzodiazepines. Clin. Chim. Acta 271, 1-9 (1998).
8. Pulini M. False-positive benzodiazepine urine test due to oxaprozin. JAMA 273, 1905-1906 (1995).
9. Sorisky, A & Watson, D.C. Positive diphenhydramine interference in the EMIT-st Assay for tricyclic antidepressants in serum. Clin. Chem. 32, 715 (1986).
10. Sena, S.F., Kazimi, S. & Wu, A.H. False-positive phencyclidine immunoassay results caused by venlafaxine and O-desmethylvenlafaxine. Clin. Chem. 48, 676-677 (2002).
11. Rossi, S., Yaksh, T., Bentley, H., Van den Brande, G., Grant, I. & Ellis, R. Characterization of interference with 6 commercial delta9-tetrahydrocannabinol immunoassays by efavirenz (glucuronide) in urine. Clin. Chem. 52, 896-897 (2006).
12. Wu, A.H.B. et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: recommendations for the use of laboratory tests to support poisoned patients who present to the emergency department. Clin. Chem. 49, 357-379 (2003).